
    
      Phase II: to determine if recruitment into a phase III trial is feasible, with a target of 10
      patients per month during a minimum of 6 months (evaluated within months 7-18 of the trial).

      Phase III: to determine whether the 5-year disease-free survival rate among patients who do
      not have routine Radioactive iodine (RAI) ablation is non-inferior to those who do.
    
  